CLIMB BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.83 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.15, a 130.56% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.80.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $8.21.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.77, a 73.86% decline from fiscal 2024.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.77, a 125.67% increase from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.00, a 47.18% decline from fiscal 2022.
- CLIMB BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.68, a 39.56% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.83 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.15 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.77 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.64 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.63 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $1.80 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $6.77 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $7.20 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $7.55 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | $3.00 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $3.00 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $3.00 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $5.68 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $7.80 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $7.83 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $8.21 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $4.07 10-K · filed 2022-03-07 | |||
| 2021-09-30 | $3.11 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $2.68 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |